A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02042248
Recruitment Status : Completed
First Posted : January 22, 2014
Last Update Posted : May 4, 2017
Argos Therapeutics
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Cynthia L Gay, MD, University of North Carolina, Chapel Hill

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : May 2016
  Actual Study Completion Date : May 2016
Tcherepanova, I, Harri, J, Horvatinovich, J, et al. Autologous dendritic cell based therapy modulates proviral DNA levels in chronically HIV-infected subjects. AIDS Vaccine 2013 7 - 10 October in Barcelona, Spain.
Wolf J, Bogner C, Hoffmann V, Avettand-Fenoel K, Schewe R, Pauli J, et al. 5-drug HAART during primary HIV infection leads to a reduction of proviral DNA levels in comparison to levels achievable during chronic infection. In: 7th IAS Conference on HIV Pathogenesis. Kuala Lumpur, Malaysia; 2013.